Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 10/20 | 0.61 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.53 |
| ▸ | BRAF | P15056 | 1/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.50 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.50 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.50 |
| ▸ | CSNK2A3 | Q8NEV1 | 2/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | IKBKB | O14920 | 1/20 | 0.50 |
| ▸ | CHUK | O15111 | 1/20 | 0.50 |
| ▸ | IKBKG | Q9Y6K9 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | RET | P07949 | 1/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.49 |
| ▸ | TYK2 | P29597 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5260063 | 0.84 | TBK1 (0.63) | TBK1PDPK1AURKAGSK3BCCNT1 | |
| SCHEMBL5259735 | 0.83 | BRAF (0.51) | BRAFAURKAPDGFRBPDGFRAGSK3B | |
| SCHEMBL5259759 | 0.83 | BRAF (0.55) | BRAFAURKAPDGFRBPDGFRAGSK3B | |
| SCHEMBL5260385 | 0.81 | BRAF (0.51) | BRAFAURKAPDGFRBPDGFRAGSK3B | |
| SCHEMBL5257635 | 0.76 | CYP2C19 (0.53) | TBK1 | |
| Trifluoroacetic Acid SCHEMBL6674348 | 0.76 | GSK3B (0.71) | TBK1PDPK1AURKAGSK3B | |
| SCHEMBL2497661 | 0.75 | BRAF (0.60) | BRAFIKBKBCHUKIKBKGFLT3 | |
| SCHEMBL6674350 | 0.73 | GSK3B (0.55) | TBK1PDPK1AURKAGSK3B | |
| SCHEMBL13898246 | 0.73 | TBK1 (0.72) | TBK1PDPK1AURKACSNK2A2TYK2 | |
| SCHEMBL29818179 | 0.72 | ATR (0.59) | BRAFCSNK2A2CSNK2BCSNK2A1CSNK2A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268444-B1 | 2,4-DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRMIDINES AS ANTINEOPLASTIC AGENTS | ASTRAZENECA AB (SE) | 2007-01-17 | — | — | EP | claimed |
| US-6649608-B2 | Cyclin-dependent serine/threonine and focal adhesion kinase inhibitors | ASTRAZENECA AB (SE) | 2003-11-18 | — | — | US | claimed |
| JP-2003525278-A | — | — | 2003-08-26 | — | — | JP | claimed |
| US-20030149266-A1 | 2,4-Di(hetero-)arylamino (oxy)-5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB (SE) | 2003-08-07 | — | — | US | claimed |
| EP-1268444-A1 | 2,4-DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRMIDINES AS ANTINEOPLASTIC AGENTS | AstraZeneca AB (SE) | 2003-01-02 | — | — | EP | claimed |
| WO-2001064655-A1 | 2, 4-DI(HETERO-)ARYLAMINO (-OXY)-5-SUBSTITUTED PYRIMIDINES AS ANTINEOPLASTIC AGENTS | ASTRAZENECA AB (SE) | 2001-09-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149266-A1 | 2,4-Di(hetero-)arylamino (oxy)-5-substituted pyrimidines as antineoplastic agents | CDK2, CCNI, CDK1 | TBK1 1920/4885PDPK1 299/4885BRAF 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.